Papers 9

  1. Bacterial DNA is implicated in the inflammatory response to delivery of DNA/DOTAP to mouse lungs.
    McLachlan G et al., Gene Ther. 2000 Mar;7(5):384-92.
  2. Plasmid DNA molecules complexed with cationic liposomes are protected from degradation by nucleases and shearing by aerosolisation.
    Crook K et al., Gene Ther. 1996 Sep;3(9):834-9.
  3. Evaluation in vitro and in vivo of cationic liposome-expression construct complexes for cystic fibrosis gene therapy.
    McLachlan G et al., Gene Ther. 1995 Nov;2(9):614-22.
  4. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis.
    Caplen NJ et al., Nat Med. 1995 Jan;1(1):39-46.
  5. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis.
    Porteous DJ et al., Gene Ther. 1997 Mar;4(3):210-8.
  6. Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMV-CFTR-DOTAP.
    McLachlan G et al., Gene Ther. 1996 Dec;3(12):1113-23.
  7. Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis
    Alton EW et al., In Press
  8. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Alton EW et al., Lancet Respir Med. 2015 Sep;3(9):684-91. doi: 10.1016/S2213-2600(15)00245-3. Epub 2015 Jul 3.
  9. A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis.
    Alton EW et al., Efficacy and Mechanism Evaluation (2016) Volume: 3 Issue: 5

Abstracts 1

  1. Moving lentiviral-based gene therapy into a first-in-man CF trial.
    Griesenbach U et al.,The North American Cystic Fibrosis Conference (2015)

 

A cake that only some of us got to enjoy!

 

Light microscope image of a human airway liquid interface cultures. Dark patches are mucous.